GlassScriptPhysician profile
Sheldon Marshall Shore
NPI 1588647697
$474,172.98
in general payments reported to CMS, 2019-2025
38 companies · $106K in 2025
The $106K reported for 2025 was more than what 99% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41K · 2020: $11K · 2021: $51K · 2022: $113K · 2023: $66K · 2024: $86K · 2025: $106K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $169K · Consulting Fee: $31K · Travel and Lodging: $18K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $15K · Food and Beverage: $15K · Honoraria: $8,925 · Education: $322.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $168,911.02 |
| Consulting Fee | $31,234.36 |
| Travel and Lodging | $18,458.79 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $15,200.00 |
| Food and Beverage | $15,129.12 |
| Honoraria | $8,925.00 |
| Education | $322.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $128,533.66 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $117,873.94 | 2019-2025 | Farxiga, Lokelma, Evusheld |
| Travere Therapeutics, INC. | $75,987.53 | 2020-2025 | Filspari |
| Otsuka America Pharmaceutical, INC. | $53,410.51 | 2019-2025 | Jynarque, Voyxact |
| Lilly USA, LLC | $28,146.07 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15,164.43 | 2023-2025 | Jardiance |
| Mallinckrodt Hospital Products INC. | $9,846.95 | 2020-2025 | Acthar, Terlivaz |
| Akebia Therapeutics INC | $9,763.79 | 2019-2025 | Vafseo, Auryxia |
| Novartis Pharmaceuticals Corporation | $7,035.72 | 2023-2025 | |
| Vifor Pharma, INC. | $6,597.64 | 2019-2024 | Veltassa, Korsuva |
| Scpharmaceuticals INC. | $6,171.01 | 2024-2025 | |
| Ani Pharmaceuticals, INC. | $4,664.91 | 2022-2025 | Purified Cortrophin Gel |
| Aurinia Pharma U.S., INC. | $3,133.81 | 2021-2024 | Lupkynis |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $2,394.86 | 2019-2025 | |
| Amgen INC. | $1,111.24 | 2019-2025 | Krystexxa, Tavneos, Parsabiv |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $786.76 | 2019-2025 | Rayaldee |
| Glaxosmithkline, LLC. | $732.59 | 2020-2025 | Benlysta, Arexvy |
| Horizon Therapeutics Plc | $727.10 | 2019-2023 | Krystexxa |
| Calliditas Therapeutics US INC. | $469.10 | 2022-2025 | Tarpeyo |
| Novo Nordisk INC | $383.82 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Fresenius USA Marketing, INC. | $330.57 | 2019-2025 | Velphoro, Velphoro |
| Daiichi Sankyo INC. | $209.62 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $135.88 | 2019-2025 | Ultomiris |
| Alnylam Pharmaceuticals INC. | $88.00 | 2020-2022 | |
| Mallinckrodt Enterprises LLC | $86.06 | 2019 | |
| Ardelyx, INC. | $84.69 | 2024-2025 | Ibsrela |
| Apellis Pharmaceuticals, INC. | $54.84 | 2025 | Empaveli |
| Idorsia Pharmaceuticals US INC | $35.99 | 2025 | Tryvio |
| Janssen Pharmaceuticals, INC | $33.54 | 2019-2020 | |
| Outset Medical INC | $32.62 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $24.45 | 2022 | |
| Genentech USA, INC. | $20.52 | 2025 | Gazyva |
| Invivyd INC | $18.32 | 2025 | Pemgarda |
| Abbvie INC. | $17.09 | 2021 | |
| Amag Pharmaceuticals, INC. | $17.00 | 2019 | |
| Vantive US Healthcare LLC | $16.88 | 2025 | Renal - Pd |
| Shire North American Group INC | $16.47 | 2019 | |
| Pfizer INC. | $15.00 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheldon Shore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.